Delpor, Inc.

Delpor, Inc. is a clinical stage life sciences company headquartered in the United States with a focus on developing innovative drug-delivery technologies for once-yearly therapies for chronic conditions. The company's lead product, a 6-12-month formulation of Risperidone, aims to provide a long-lasting treatment for schizophrenia. In addition to this, Delpor is also working on developing extended-release formulations for other drugs targeting CNS conditions such as Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders. Since its establishment in 2009, Delpor has positioned itself as a key player in the Biopharma and Biotechnology industries with a clear mission of addressing unmet medical needs through its innovative drug delivery solutions. In November 2021, the company secured a $2.50M grant investment from the National Institutes of Health, further demonstrating the confidence that notable organizations have in Delpor's approach and potential impact in the field of long-acting drug therapies. Overall, Delpor, Inc. is dedicated to revolutionizing treatment options for chronic conditions through its pioneering once-yearly therapy approach and continues to attract significant support from influential entities in the medical and investment communities.